pvx-410
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 12, 2017 (NCT03362060)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSW7QU8GP4UY ↗
- NCATSV1QJC0TIE6 ↗
- NCATSEHT3VE7CI1 ↗
- NCATS7AS3WP8FO8 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04634747 | Phase 2 | Apr 1, 2021 | OncoPep, Inc. |
| NCT03362060 | Phase 1 | Dec 12, 2017 | Harvard University, Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| OncoPep, Inc. | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1